One Week's Treatment with the Long-Acting Glucagon-Like Peptide 1 Derivative Liraglutide (NN2211) Markedly Improves 24-h Glycemia and α- and β-Cell Function and Reduces Endogenous Glucose Release in Patients with Type 2 Diabetes

Diabetes

Volumn 53, Issue 5, 2004, Pages 1187-1194

  Degn, Kristine B ^d   Juhl, Claus B ^d   Sturis, Jeppe ^a   Jakobsen, Grethe ^a   Brock, Birgitte ^d   Chandramouli, Visvanathan ^b   Rungby, Joergen ^d   Landau, Bernard R ^b   Schmitz, Ole ^c  

^a NOVO NORDISK A S   (Denmark)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; C PEPTIDE; FATTY ACID; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; LIRAGLUTIDE; METFORMIN; PANCREAS HORMONE; PARACETAMOL; PLACEBO; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG HALF LIFE; DRUG MECHANISM; FATTY ACID BLOOD LEVEL; FEMALE; GLUCAGON BLOOD LEVEL; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HOMEOSTASIS; HORMONE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RELEASE; KIDNEY DISEASE; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETINOPATHY; STOMACH EMPTYING; TREATMENT OUTCOME;

CIRCADIAN RHYTHM; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTRIC EMPTYING; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HORMONES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; ISLETS OF LANGERHANS; MALE; MIDDLE AGED;

EID: 2342599057     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.53.5.1187     Document Type: Article

References (45)

1. Ferrannini E: Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev 19:477-490, 1998
2. Consoli A, Nuijhan N, Capani F, Gerich J: Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM. Diabetes 38:550-557, 1989
3. Magnusson I, Rothman DL, Katz LD, Shulman RG, Shulman GI: Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. J Clin Invest 90:1323-1327, 1992
4. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA: Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 85:4053-4059, 2000
5. Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB: Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 64:106-110, 1987
6. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ: Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50:609-613, 2001
7. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): U.K. Prospective Diabetes Study (UKPDS) Group. Lancet 352:837-853, 1998
8. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-393, 2003
9. Nauck MA: Is glucagon-like peptide 1 an incretin hormone? Diabetologia 42:373-379, 1999
10. Stoffers DA, Kieffer TJ, Hussain MA, Drucker DJ, Bonner-Weir S, Habener JF, Egan JM: Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 49:741-748, 2000
11. Flint A, Raben A, Astrup A, Holst JJ: Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101:515-520, 1998
12. Zander M, Madsbad S, Madsen JL, Holst JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359: 824-830, 2002
13. Meneilly GS, Grieg N, Tildesley H, Habener JF, Egan JM, Eliha D: Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes. Diabetes Care 26:2835-2841, 2003
14. 2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44:1126-1131, 1995
15. Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M: The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 45:195-202, 2002
16. Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agerso H, Veldhuis J, Porksen N, Schmitz O: Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 51:424-429, 2002
17. Matthews D, Madsbad S, Schmitz O, Lagendorf KW, Jakobsen G: The long-acting GLP-1 derivative, NN2211, a new agent for the treatment of type 2 diabetes (Abstract). Diabetes 51 (Suppl. 2):A84, 2002
18. Clements JA, Heading RC, Nimmo WS, Prescott LF: Kinetics of acetaminophen absorption and gastric emptying in man. Clin Pharmacol Ther 24: 420-431, 1978
19. Hother-Nielsen O, Mengel A, Moller J, Rasmussen O, Schmitz O, Beck-Nielsen H: Assessment of glucose turnover rates in euglycaemic clamp studies using primed-constant [3-3H]-glucose infusion and labelled or unlabelled glucose infusates. Diabet Med 9:840-849, 1992
20. Landau BR, Wahren J, Chandramouli V, Schumann WC, Ekberg K, Kalhan SC: Contributions of gluconeogenesis to glucose production in the fasted state. J Clin Invest 98:378-385, 1996
21. Finegood DT, Bergman RN, Vranic M: Estimation of endogenous glucose production during hyperinsulinemic-euglycemic glucose clamps: comparison of unlabeled and labeled exogenous glucose infusates. Diabetes 36:914-924, 1987
22. Polonsky KS, Licinio-Paixao J, Given BD, Pugh W, Rue P, Galloway J, Karrison T, Frank B: Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients. J Clin Invest 77:98-105, 1986
23. Van Cauter E, Mestrez F, Sturis J, Polonsky KS: Estimation of insulin secretion rates from C-peptide levels: comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 41:368-377, 1992
24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
25. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP, Porte D Jr: Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects: evidence for a hyperbolic function. Diabetes 42:1663-1672, 1993
26. American Diabetes Association: Standards of medical care for patients with diabetes mellitus. Diabetes Care 25 (Suppl. 1):S33-S49, 2002
27. Larsen J, Hylleberg B, Ng K, Damsbo P: Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment Diabetes Care 24:1416-1421, 2001
28. Butler PC, Rizza RA: Contribution to postprandial hyperglycemia and effect on initial splanchnic glucose clearance of hepatic glucose cycling in glucose-intolerant or NIDDM patients. Diabetes 40:73-81, 1991
29. Nauck MA, Wollschlager D, Wemer J, Holst JJ, Orskov C, Creutzfeldt W, Willms B: Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 39:1546-1553, 1996
30. Naslund E, Bogefors J, Gryback P, Jacobsson H, Hellstrom PM: Gastric emptying: comparison of scintigraphic, polyethylene glycol dilution, and paracetamol tracer assessment techniques. Scand J Gastroenterol 35:375-379, 2000
31. Ribel U, Larsen MO, Rolin B, Carr RD, Wilken M, Sturis J, Westergaard L, Deacon CF, Knudsen LB: NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs. Eur J Pharmacol 451:217-225, 2002
32. Singhal P, Caumo A, Carey PE, Cobelli C, Taylor R: Regulation of endogenous glucose production after a mixed meal in type 2 diabetes. Am J Physiol Endocrinol Metab 283:E275-E283, 2002
33. Dinneen S, Alzaid A, Turk D, Rizza R: Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. Diabetologia 38:337-343, 1995
34. Wajngot A, Chandramouli V, Schumann WC, Ekberg K, Jones PK, Efendic S, Landau BR: Quantitative contributions of gluconeogenesis to glucose production during fasting in type 2 diabetes mellitus. Metabolism 50:47-52, 2001
35. Gastaldelli A, Baldi S, Pettiti M, Toschi E, Camastra S, Natali A, Landau BR, Ferrannini E: Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. Diabetes 49:1367-1373, 2000
36. Cherrington AD: Banting Lecture 1997: control of glucose uptake and release by the liver in vivo. Diabetes 48:1198-1214, 1999
37. Magnusson I, Rothman DL, Gerard DP, Katz LD, Shulman GI: Contribution of hepatic glycogenolysis to glucose production in hurhans in response to a physiological increase in plasma glucagon concentration. Diabetes 44: 185-189, 1995
38. Turner R, Cull C, Holman R: United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 124:136-145, 1996
39. Porte D Jr: Banting Lecture 1990: β-cells in type II diabetes mellitus. Diabetes 40:166-180, 1991
40. Mahler RJ, Adler ML: Clinical review 102: type 2 diabetes mellitus: update on diagnosis, pathophysiology, and treatment. J Clin Endocrinol Metab 84:1165-1171, 1999
41. Ahren B, Larsson H, Holst JJ: Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:473-478, 1997
42. Nyholm B, Walker M, Gravholt CH, Shearing PA, Sturis J, Alberti KG, Holst JJ, Schmitz O: Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of type II (non-insulin-dependent) diabetic parents: evidence of several aberrations. Diabetologia 42:1314-1323, 1999
43. Kahn SE, Halban PA: Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes 46:1725-1732, 1997
44. Roder ME, Porte D Jr, Schwartz RS, Kahn SE: Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 83:604-608, 1998
45. Stumvoll M, Tataranni PA, Stefan N, Vozarova B, Bogardus C: Glucose allostasis. Diabetes 52:903-909, 2003